Research
Hormonal
GLP-1 receptor agonists (semaglutide 2.4 mg) and other pharmacological interventions (liraglutide, orlistat) significantly reduce body weight and cardiovascular risk factors in obese patients, with semaglutide showing superior weight loss compared to placebo.
For obese individuals without diabetes, high-dose semaglutide (2.4 mg) can achieve substantial weight loss (approx. 15%) compared to placebo, which may improve cardiovascular risk factors. This is a viable option when lifestyle changes are insufficient.
GoodSupportsHIGH confidence
Recently semaglutide at 2.4 mg dose in obese patients without diabetes has demonstrated a significant body weight reduction (14.9% vs. 2.4% with placebo). In total, 69% of body weight reduction ≥10% at 68 weeks and 50% body weight reduction ≥15%.
Why this rating
Cites specific clinical trials (LEADER, etc.) and outcomes.
Source
Obesity and Cardiovascular Risk
P. Velasco · IntechOpen eBooks · 2023
DOI 10.5772/intechopen.106877
book_chapterCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity increases cardiovascular risk and mortality primarily through visceral adiposity and ectopic fat deposition (pericardial/epicardial), which drive endothelial dysfunction, chronic inflammation, and atherosclerosis, independent of or additive to traditional risk factors like BMI, blood pressure, and cholesterol.Good
- Aerobic exercise reduces visceral adipose tissue (VAT) independently of weight loss, and 150 minutes per week is sufficient for this reduction, whereas resistance training effects on VAT are equivocal.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →